This week we've had EyesOn clinical data and approvals for therapies in hematology and neurology. Check out the news onVertex's gene therapy approval for patients as young as 2-years old, Orca's allogeneic cell therapies approval for GVHD, and Ipsen's neurotoxin Phase 3 data showing efficacy in both episodic and chronic migraines.

We've had Eyes On recent news further clarifying company restructures. In the midst of refining pipelines, and cutting corporate spending ..

Following up on our previous post about Gene Therapies, we are sharing data on Genetic Medicines in development - pipelines, targets, dates

We've been keeping Eyes On the Gene Therapy area - and thought we would post some general information about the area ...

This week, the team had Eyes on the new draft guidance from the US FDA on Gene Therapy Products Incorporating Genome Editing.